Bluejay Diagnostics (BJDX) Liabilities and Shareholders Equity (2020 - 2026)

Bluejay Diagnostics has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $5.6 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $5.6 million, up 6.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.0 million (down 22.91% YoY), and the FY2025 annual result was $7.1 million, up 6.94% from the prior year.
• Liabilities and Shareholders Equity came in at $5.6 million for Q1 2026 at Bluejay Diagnostics, down from $7.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $20.1 million in Q1 2022 to a low of $4.9 million in Q4 2023.
• The 5-year median for Liabilities and Shareholders Equity is $8.2 million (2023), against an average of $9.4 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 333.54% in 2022 and slumped 63.99% in 2023, its largest moves.
• Bluejay Diagnostics' Liabilities and Shareholders Equity stood at $13.5 million in 2022, then plunged by 63.99% to $4.9 million in 2023, then surged by 36.74% to $6.7 million in 2024, then grew by 6.94% to $7.1 million in 2025, then slipped by 21.36% to $5.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $5.6 million (Q1 2026), $7.1 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.